These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27562794)

  • 1. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
    Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
    Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
    Ayinde O; Wang Z; Griffin M
    Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
    Kumar S; Donti TR; Agnihotri N; Mehta K
    Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
    Agnihotri N; Kumar S; Mehta K
    Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
    Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
    Meshram DD; Pike CVS; Coussons PJ
    Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complex role of transglutaminase 2 in glioblastoma proliferation.
    Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
    Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
    Brown KD
    Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
    Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
    Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue transglutaminase: a new target to reverse cancer drug resistance.
    Budillon A; Carbone C; Di Gennaro E
    Amino Acids; 2013 Jan; 44(1):63-72. PubMed ID: 22130737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue transglutaminase promotes or suppresses tumors depending on cell context.
    Chhabra A; Verma A; Mehta K
    Anticancer Res; 2009 Jun; 29(6):1909-19. PubMed ID: 19528447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.
    Akar U; Ozpolat B; Mehta K; Fok J; Kondo Y; Lopez-Berestein G
    Mol Cancer Res; 2007 Mar; 5(3):241-9. PubMed ID: 17374730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
    Kotsakis P; Wang Z; Collighan RJ; Griffin M
    Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
    Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
    Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.